Justin D. Salciccioli

Justin D. Salciccioli

Auto-generated profile, based on publicly available information

Justin D. Salciccioli

Department of Critical Care, Brigham and Women's Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
WHWill Hughes
Will Hughes
RGRichard Goodall
Richard Goodall
JSJustin D. Salciccioli
Justin D. Salciccioli
DMDominic C. Marshall
Dominic C. Marshall
ADAlun H. Davies
Alun H. Davies
JSJoseph Shalhoub
Joseph Shalhoub


28 July 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RGRichard Goodall
Richard Goodall
AAAndrew Alazawi
Andrew Alazawi
WHWill Hughes
Will Hughes
VBVassiliki Bravis
Vassiliki Bravis
JSJustin D. Salciccioli
Justin D. Salciccioli
JSJoseph Shalhoub
Joseph Shalhoub
This observational study aimed to assess trends in type 2 diabetes mellitus (T2DM) disease burden in European Union countries for the years 1990–2019. Sex specific T2DM age-standardised prevalence (ASPRs), mortality (ASMRs) and disability-adjusted life-year rates (DALYs) per 100,000 population were extracted from the Global Burden of Disease (GBD) Study online results tool for each EU country (inclusive of the United Kingdom), for the years 1990–2019. Trends were analysed using Joinpoint regression analysis. Between 1990 and 2019, increases in T2DM ASPRs were observed for all EU countries. The highest relative increases in ASPRs were observed in Luxembourg (males + 269.1%, females + 219.2%), Ireland (males + 191.9%, females + 165.7%) and the UK (males + 128.6%, females + 114.6%). Mortality trends were less uniform across EU countries, however a general trend towards reducing T2DM mortality was observed, with ASMRs decreasing over the 30-year period studied in 16/28 countries for males and in 24/28 countries for females. The UK observed the highest relative decrease in ASMRs for males (− 46.9%). For females, the largest relative decrease in ASMRs was in Cyprus (− 67.6%). DALYs increased in 25/28 countries for males and in 17/28 countries for females between 1990 and 2019. DALYs were higher in males than females in all EU countries in 2019. T2DM prevalence rates have increased across EU countries over the last 30 years. Mortality from T2DM has generally decreased in EU countries, however trends were more variable than those observed for prevalence. Primary prevention strategies should continue to be a focus for preventing T2DM in at risk groups in EU countries.

1 September 2023 in JCO Global Oncology
Verified
Journal Article
Open access
CJChinmay T. Jani
Chinmay T. Jani
AAAlaaeldin Ahmed
Alaaeldin Ahmed
HSHarpreet Singh
Harpreet Singh
CMChristian F Mouchati
Christian F Mouchati
OOOmar Al Omari
Omar Al Omari
PLPrudence Lam
Prudence Lam
PURPOSE: AML accounts for 80% of acute leukemia in adults. While progress has been made in treating younger patients in the past 2 decades, there has been limited improvement for older patients until recently. This study examines the global and European Union (EU) 15+ trends in AML between 1990 and 2019. METHODS: We extracted age-standardized incidence rates (ASIRs), age-standardized death rates (ASMRs), and disability-adjusted life years, stratified by sex from the Global Burden of Disease Study database, and mortality-to-incidence ratio (MIR) were computed. Trends were compared using Joinpoint regression. RESULTS: The findings show a global increase in AML incidence for both sexes from 1990 to 2019. In the EU15+ countries, most countries exhibited an increase in ASIR for both sexes. Joinpoint revealed that globally for male patients, ASIR steadily increased until 2010, remained stable until 2015 followed by a decline till 2019. Similar trends were observed in female patients. For ASMR, although there was an increase globally and in most EU15+ countries, there was a statistically significant decrease in mortality rates globally and in the majority of EU15+ countries in recent years. MIR improved in both sexes globally. On age stratification, AML burden was highest among older groups (55 years and older), while the lowest rates were observed in younger than 20 years. CONCLUSION: The findings from our study indicate a global rise in AML incidence and mortality in both sexes and decrease in MIR from 1990 to 2019 suggesting a better survival. However, on Joinpoint analysis, there is no change in MIR in women in the past decade and past 4 years in men indicating plateau in survival trends despite recent advances.

25 January 2021 in European Heart Journal
Verified
Journal Article
Closed access
BABecker M Al-Khayatt
Becker M Al-Khayatt
JSJustin D Salciccioli
Justin D Salciccioli
DMDominic C Marshall
Dominic C Marshall
AKAndrew D Krahn
Andrew D Krahn
JSJoseph Shalhoub
Joseph Shalhoub
MSMarkus B Sikkel
Markus B Sikkel
Aims: The aim of this study was to understand the changing trends in atrial fibrillation (AF) incidence and mortality across Europe from 1990 to 2017, and how socioeconomic factors and sex differences play a role. Methods and results: We performed a temporal analysis of data from the 2017 Global Burden of Disease Database for 20 countries across Europe using Joinpoint regression analysis. Age-adjusted incidence, mortality, and mortality-to-incidence ratios (MIRs) to approximate case fatality rate are presented. Incidence and mortality trends were heterogenous throughout Europe, with Austria, Denmark, and Sweden experiencing peaks in incidence in the middle of the study period. Mortality rates were higher in wealthier countries with the highest being Sweden for both men and women (8.83 and 8.88 per 100 000, respectively) in 2017. MIRs were higher in women in all countries studied, with the disparity increasing the most over time in Germany (43.6% higher in women vs. men in 1990 to 74.5% higher in women in 2017). Conclusion: AF incidence and mortality across Europe did not show a general trend, but unique patterns for some nations were observed. Higher mortality rates were observed in wealthier countries, potentially secondary to a survivor effect where patients survive long enough to suffer from AF and its complications. Outcomes for women with AF were worse than men, represented by higher MIRs. This suggests that there is widespread healthcare inequality between the sexes across Europe, or that there are biological differences between them in terms of their risk of adverse outcomes from AF.

4 May 2018 in Respiratory Research
Verified
Journal Article
Open access
PDF file
DMDominic C. Marshall
Dominic C. Marshall
RGRoss J. Goodson
Ross J. Goodson
YXYiwang Xu
Yiwang Xu
MKMatthieu Komorowski
Matthieu Komorowski
JSJoseph Shalhoub
Joseph Shalhoub
JSJustin D. Salciccioli
Justin D. Salciccioli
Pneumonia is responsible for approximately 230,000 deaths in Europe, annually. Comprehensive and comparable reports on pneumonia mortality trends across the European Union (EU) are lacking. A temporal analysis of national mortality statistics to compare trends in pneumonia age-standardised death rates (ASDR) of EU countries between 2001 and 2014 was performed. International Classification of Diseases version 10 (ICD-10) codes were used to extract data from the World Health Organisation European Detailed Mortality Database and trends were analysed using Joinpoint regression. Median pneumonia mortality across the EU for the last recorded observation was 19.8 / 100,000 and 6.9 / 100,000 for males and females, respectively. Mortality was higher in males across all EU countries, most notably in Estonia and Lithuania where the ratio of male to female ASDR was 4.0 and 3.7, respectively. Gender mortality differences were lowest in the UK and Demark with ASDR ratios of 1.1 and 1.5, respectively. Pneumonia mortality across all countries decreased by a median of 31.0% over the observation period. Countries that demonstrated an increase in pneumonia mortality were Poland (males + 33.1%, females + 10.2%), and Lithuania (males + 6.0%). Mortality from pneumonia is improving in most EU countries, however substantial variation in trends remains between countries and between genders.